STOCK TITAN

Unicycive Therapeutics Inc - UNCY STOCK NEWS

Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.

Unicycive Therapeutics Inc (UNCY) is a clinical-stage biotechnology company pioneering novel treatments for kidney diseases, including hyperphosphatemia and acute kidney injury. This page aggregates all corporate announcements, regulatory updates, and research milestones related to its innovative pipeline.

Investors and healthcare professionals will find timely updates on clinical trial progress, partnership developments, and financial disclosures. Our curated collection includes press releases about Renazorb (phosphate-binding therapy) and UNI-494 (acute kidney injury treatment), along with strategic business decisions impacting the company's trajectory.

Key content categories include FDA communications, peer-reviewed study publications, intellectual property updates, and earnings reports. All materials are sourced directly from official company channels to ensure accuracy and compliance with financial disclosure standards.

Bookmark this page for streamlined access to UNC's latest developments in renal therapeutics. Regularly updated to reflect new breakthroughs in drug development and corporate strategy, it serves as an essential resource for monitoring this innovative biotech's progress.

Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) will have its CEO present a company update at a healthcare conference. The webcast will be available for three months on the Unicycive website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announces financial results for 2023, highlights progress in clinical development programs OLC and UNI-494. OLC topline data expected in Q2 2024, UNI-494 granted orphan drug designation for delayed graft function in acute kidney injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announces multiple presentations on product candidates at the 61st European Renal Association Congress. The presentations will cover oxylanthanum carbonate (OLC) and UNI-494, focusing on preclinical data and ongoing clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
Rhea-AI Summary
Unicycive Therapeutics, Inc. announces a private placement of 50,000 shares of Series B Convertible Preferred Stock at $1,000 per share, totaling $50 million. The financing, led by Octagon Capital and Great Point Partners, LLC, aims to support clinical development programs for kidney disease therapies, notably Oxylanthanum Carbonate (OLC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
none
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) reports positive preclinical results for UNI-494 in Delayed Graft Function of Acute Kidney Injury. Phase 1 Single Ascending Dose portion of the clinical trial is complete, showcasing promising developments in kidney disease therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. completes enrollment in pivotal clinical trial for Oxylanthanum Carbonate to treat hyperphosphatemia in CKD patients. Topline data expected in Q2, 2024 with a plan to file NDA thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) receives orphan drug designation from the FDA for UNI-494, a cytoprotective agent to prevent Delayed Graft Function (DGF) in kidney transplant patients. The designation may provide tax credits, fee exemptions, and market exclusivity. UNI-494's mechanism of action shows promise in addressing this serious complication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) will present new data on the bioequivalence study for its lead product candidate, oxylanthanum carbonate (OLC), at the National Kidney Foundation Spring Clinical Meeting. The Company aims to address patient non-compliance issues with phosphate binders through survey results, contributing to the healthcare community's knowledge on kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.48%
Tags
conferences
-
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) announced new preclinical data on UNI-494, a clinical-stage biotechnology company developing therapies for patients with kidney disease. The data will be presented at the 29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024 in San Diego, CA, showcasing the efficacy of UNI-494 in animal models of delayed graft function and describing the ongoing Phase 1 clinical trial design for UNI-494 in healthy volunteers. The company's primary focus remains on advancing its lead drug, OLC, towards a New Drug Application submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.43%
Tags
none
Rhea-AI Summary
Unicycive Therapeutics, Inc. (UNCY) issues a letter to shareholders, highlighting the progress made in its clinical programs, especially with the lead program OLC, a next-generation lanthanum-based phosphate binding agent. The company expects to report topline data from the pivotal clinical trial for OLC in Q2 2024, targeting the multibillion-dollar hyperphosphatemia market. Additionally, the company continues to advance its second compound UNI-494 for the treatment of acute kidney injury and chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.29%
Tags
none
Unicycive Therapeutics Inc

Nasdaq:UNCY

UNCY Rankings

UNCY Stock Data

71.86M
113.35M
6.12%
60.39%
1.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
LOS ALTOS